

What the Coppertone Girl Didn't Know –Neoplasms

**Victoria Lazareth MA, MSN, NP-C, DCNP
Dermatology Nurse Practitioner, MA**

Disclosures

Advisory Board

- Bristol Myers Squibb -Psoriasis
- Incite -Vitiligo
- JDNPPA -Dermatology
- UCB -Psoriasis

Speaker Panel

- American Association of Nurse Practitioners -Dermatology
- Dermatology Nurses' Association -Dermatology
- MauiDerm NP+PA -Dermatology
- Nurse Practitioner Association for Continuing Education -Dermatology

Objectives

Upon completion of this presentation the participant will

- Classify common features of benign skin lesions
- Recognize risk factors for developing skin cancers
- Identify suspicious features which may indicate a malignant lesion
- Discuss appropriate management of non-melanoma skin cancers
- Describe interventions to optimize outcomes in patients with melanoma

Benign Lesions

Seborrheic Keratosis

- benign
- most common tumor of the skin
- well-demarcated, elevated or "stuck on" appearing papules or plaques
- skin-colored to shades of yellow, gray, brown, or black
- "waxy" or "greasy" surface
- can develop anywhere except palms, soles, mucous membranes



Seborrheic Keratosis: subtypes

hyperkeratotic, irritated/inflamed, reticulated, pigmented

reticulated SK (variation in color w ridges)



Seborrheic Keratosis: variants

Dermatosis Papulosa Nigrans

1 – 2mm dark papules concentrated around the eyes & malar cheeks



Stucco keratosis

small white papules
distal parts of the lower limbs



Seborrheic Keratosis: ddx

- Melanoma
- Verruca
- Actinic keratosis
- Lentigo maligna
- Melanocytic nevus
- Squamous cell carcinoma
- Pigmented basal cell carcinoma



Acrochordon

- Tags: common benign fleshy papules occurring in the skinfolds
- >30 yrs, obese
- easily irritated
- tender when traumatized, twisted, torn, thrombosed
- Acrochordons: 1-5 mm
- skin-colored – brown papule
- soft, fleshy pedunculated



Syringoma

- Small, benign, firm, skin-colored - yellow papules
- F, eyelids, upper chest, vulva
- asymptomatic, stable, persistent



Sebaceous Hyperplasia

- common benign enlarged sebaceous gland
- middle age – older adults
- 1-4 mm soft skin-colored – pale yellow smooth umbilicated papule
- asymptomatic, persistent
- may be associated with emollient moisturizers, make-up, sunscreens
- Ddx: early BCC, Molluscum Contagiosum



Fibrous papule

DDx

- BCC
- Keratoacanthoma
- Molluscum Contageosum



Chondrodermatitis Nodularis Helicis

- Inflammatory condition of the helical ear cartilage
- 2-4 mm firm tender pink – red papule with central keratotic punctum
- irritated – exquisitely tender papule
- lateral edge of the helix or antihelix
- >40 yrs
- sleeps on the affected side; CPAP mask; ball cap
- DDx: wart, Actinic Keratosis, BCC, SCC (Keratoacanthoma, SCCis)

CNH



BCC



Cyst

- common, benign lesion that has a firm consistency, a pore-like opening (central punctum) and contains macerated keratin and lipid-rich debris
- asymptomatic, waxes & wanes, but may be painful if ruptured or infected
- 0.5 – 5 cm scalp, postauricular, posterior neck, truncal nodule
- epidermal cyst walls are fairly fragile and prone to rupture creating acute inflammation
- DDx: milium, lipoma, BCC, amelanotic MM



Cyst

Pilar (trichilemmal) cysts

- common, benign, smooth, mobile, keratin filled cysts from the sheath of the hair follicle
- frequently multiple, may become large, tender, associated with overlying alopecia



Digital Myxoid Cyst

ddx: xanthoma, Rheumatoid nodule



EIC: Rx

- Infection is rare but should be treated with incision & drainage, and if fluctuant, oral antibiotics (cephalexin, doxycycline, trimethoprim-sulfamethoxazole)
- Excision should be delayed until the infection has subsided
- Inflamed (non-infected) cysts may respond to intralesional triamcinolone though intralesional steroids may cause hypopigmentation hypopigmentation or atrophy.
- Incision and drainage can provide immediate reduction in pressure and discomfort, but without removing the epidermal lining, the cyst will refill with new layers of soft keratin.
- Using a punch biopsy to create a small skin opening and then using a curette to remove the cyst wall is sometimes effective.
- Alternatively, the entire cyst, along with the wall, can be excised surgically

Lipoma

- soft, painless, 1 cm - >10 cm subcutaneous mass
- most commonly seen on the trunk, but can be located anywhere on the body
- Angiolipoma: often painful, <2 cm, well-circumscribed; forearm of teens or young adults
- Angiomyolipomas: acral locations of adult males
- Liposarcomas: deep-seated tumors; thighs, retroperitoneum
- ultrasound or CT scan *before* surgery if:
 - large size (>10 cm), rapid growth, pain
 - fixation to underlying tissues, location in deep tissues, thigh, or retroperitoneal space
- Refer to Plastics, General Surgery or Derm



Cherry Angioma

- common type of benign acquired vascular proliferation of the skin
- etiology: aging, genetic mutation, pregnancy
- asymptomatic, can bleed with trauma
- bright red, flat 1-5 mm smooth dome shaped – polypoid papules
- head, neck, trunk, extremities
- DDx: hemangioma, insect bite, venous lake, Pyogenic Granuloma, Kaposi's sarcoma



Prurigo Nodularis

- Chronic variant of Atopic Dermatitis
- nodular variant of Lichen Simplex Chronicus
- reddish, brown, hyperpigmented dome-shaped papules & nodules
- crusted, extremely pruritic, excoriated lesions at pretibial lower legs and extensor UE's
- resolve with postinflammatory hyperpigmentation
- DDx: Dermatofibroma, Lichen Simplex Chronicus, SCC, BCC, Sarcoidosis



Dermatofibroma

- common, benign growth of dermal fibrous tissue
- skin-colored, brown, red, purple
- smooth or scaly
- domed, flat or depressed papule or nodule
- firm, pea-sized papule which is fixed to the surrounding dermis; “dimples” with pressure
- DDx: dysplastic nevus, blue nevus, melanocytic nevus, keloid/hypertrophic scar, DFSP, Purigo Nodularis, Spitz, pigmented BCC, SCC, MCC, Melanoma



Keloid

- overgrowth of dense fibrous tissue which extends beyond the area of original injury
- randomly organized collagen fibers in a dense connective tissue matrix
- pts of Hispanic, Asian & African descent are particularly prone
- DDx: Dermatofibroma, xanthogranuloma, sebaceous cyst, lipoma, Sarcoidosis, recurrence of original tumor, Dermatofibromasarcoma Protuberans (DFSP)



Keloid: Rx

- 2024 consensus-based recommendations for IL corticosteroid administration (ICA)
- 1st line treatment for keloids <10 cm² with an elevation 0.3-1 cm
- 40 mg/mL triamcinolone acetonide (TAC) using a 1 mL syringe is preferred
- consider combining other treatment options in cases in which the required cumulative dose is >80 mg of TAC per session
- suggested interval of 4 weeks between TAC treatment sessions
- consider topical anesthetics such as lidocaine/prilocaine cream before ICA. combining an intralesional corticosteroid with a local anesthetic is not recommended
- blanching is the endpoint of infiltration with injection directly into keloid tissue

https://www.dermatologyadvisor.com/news/consensus-statement-issued-for-intralesional-corticosteroid-use-keloids/?utm_source=eloqua&utm_medium=email&utm_campaign=NWLTR_DER_UPDT_RSS2-Lasso2-SLI-9467_103024_AF&hmemail=&sha256email=36ba749737ebc95b6e8b16439932cfbd83ff6b6794992dae074b889a7b90f1fc&hmsubid=&nid=&elqtrack=True

Nevus sebaceous

- congenital lesion of scalp, head, neck
- linear/ oval, skin-colored/ yellow, 1-3 cm plaque
- ~20% undergo neoplastic change and can develop benign or low-grade malignant tumors
- ~7% develop Basal Cell Carcinoma
- DDx: linear epidermal nevus



Oral Lesions

Venous Lake

- Common vascular neoplasm
- generally >60 yrs
- dark blue to purple macules or papules



Oral Fibroma

- Common oral neoplasm
- reactive fibrous hyperplasia
- from trauma or irritation
- asymptomatic, smooth, firm, solitary papules



Oral Lesions

Pyogenic Granuloma

- common vascular hyperplasia of skin & mucous membranes
- associated with trauma (fingers, toes) or pregnancy/OCP hormonal factors (lips)
- benign, red, purple, rapidly growing, dome shaped papules or nodules



Mucocele Cyst

- common, mucous filled, blister-like lesion of minor salivary glands of the oral cavity
- associated with trauma; easily ruptured
- Refer to Oral Surgeon



Nail Lesions



Median Nail Dystrophy (tic)



Subungual Hematoma

Nail Lesions



Subungual Wart



Squamous Cell Carcinoma

Pre-Cancerous Lesions

Question 1

Approximately how many (pre-cancerous) Actinic Keratoses advance to SCC?

- A. 10%
- B. 20%
- C. 80%
- D. 90%

Immunosuppression

- Increases risk for developing skin cancer
 - M > F
 - age >50
 - outdoor work/hobby
- Disease related
 - CLL: *marked increase* in recurrence, metastasis and death from NMSC
 - HIV, DM, malnutrition, substance abuse
- Drug related
 - Organ Transplant Recipient (OTR):
 - number of anti-rejection drugs, increased dose, years of treatment




Immunosuppression

Incidence in OTR

- 40-70% of OTRs will develop NMSC
- heart & lung txp > kidney & liver txp
- *all* cardiac and renal OTRs will develop new NMSCs within 5 yrs of the 1st
- 2-3x the rate of melanoma with increasing incidence over time

Tumor Behavior in OTR

- very aggressive
- significant morbidity & mortality
- higher risk: recurrence, metastasis, recurrence after treatment of metastasis



Actinic Keratoses (AKs)

- intra-epidermal pre-cancerous precursors to SCC

Pathogenesis

- UVR induces cellular mutations which result in formation of atypical keratinocytes

Behavior

- 20% of AKs progress into Squamous Cell Carcinoma (SCC)
- notably those at the scalp, ear, lip
- no way to know clinically which lesions will regress or progress to SCC

Biopsy

- tender, enlarging, bleeding, resistant or recurrent lesions



AK -Treatment

Cryotherapy (liquid nitrogen)


- Individual lesions

AEs: alopecia, blistering, cartilage necrosis, erosive pustular dermatosis, exuberant granulation tissue/pyogenic granuloma, hemorrhagic blistering, hyperpigmentation, hypopigmentation, infection, nerve damage, pain, permanent nail dystrophy, lacrimal duct obstruction, scarring of free nail margin, swelling

Field Cancerization

- multiple, diffuse AKs
- contiguous areas with subclinical, nonvisible sun damage
- Field therapy limits the development of SCC

tirbanibulin ointment, fluorouracil cream, imiquimod cream
Photodynamic therapy (topical 5-aminolevulinic acid + blue light)




Non-Melanoma Skin Cancers

Case #1

47 yr M

- Rt thumb has been treated with betamethasone and moisturizers x 1.5 yrs for presumptive eczema



Squamous Cell Carcinoma (SCC)

malignant epithelial tumor

- arises from a proliferation of keratinocytes “squamous cells”
- constitutes 20% of all cutaneous malignancies

2nd most common skin cancer

- doubled the rate over the last 40 yrs
- 50% of SCC pts will have a new SCC within 5 yrs of first

aggressiveness varies wildly

- SCC In Situ may never progress whereas
- poorly differentiated SCC have potential to metastasize

Squamous Cell Carcinoma

- epidermis is comprised of keratinocytes
- cells slowly migrate to the surface
- SCC is malignant epithelial tumor
- arising from a proliferation of keratinocytes “squamous cells”
- usually successfully treated, however;
- persistent/ recurrent tumors penetrate underlying tissues
- spread to lymph nodes, distant organs

Low risk lesions

- arise from chronic UVB, heavy metals (arsenic) & chemical carcinogens (tar) exposure



Squamous Cell Carcinoma

High risk lesions

- often secondary to scarring or chronic inflammation (ie, Lupus);
- Lymphoproliferative disease (CLL)
independent risk factor for SCC;
- HIV pts
3x more likely to develop SCC (HPV);
- Immunosuppression (OTR) markedly
increases risk of cutaneous cancers
- Peri-neural / Peri-vascular/ Single cell



SCC: incidence

- SCC development in sun exposed skin
 - Caucasians ~70% head & neck; 15% UE's
 - multiple AKs: >20 AKs increases the risk of SCC development to 20%
- SCC development in sun protected skin
 - 22% of SCCs in OTRs
 - 8% of SCCs in darker skin types (most common skin ca in African-Americans)
- SCCs development at sites of chronic inflammation & infection
 - Trauma: burns, scars, ulcers, long-standing sores (HPV, Discoid Lupus)
 - Skin previously exposed to XRT, PUVA, chemicals (arsenic, petroleum by-products)

SCC: risk

Anti-rejection drugs

- Initial OTR treatment regime often includes 3 anti-rejection drugs
 - prednisone (>20 mg x weeks or months)
 - effect on cutaneous immune cells increases skin cancer risk
 - antimetabolite (azathioprine, mycophenolate mofetil)
 - effect on T-cells and B-cells increases skin cancer risk
 - calcineurin inhibitor (cyclosporin, tacrolimus)
 - direct carcinogenic effect on keratinocytes

Other medications

- BRAF inhibitors (for metastatic melanoma), TNF inhibitors (for psoriasis)

Pt education

- Risk of NMSC development increases over time post transplant, Refer to Derm

SCC: superficial (Bowens Disease)

- red scaly plaque
- usually > 1cm in size
- often misdiagnosed as psoriasis, eczema
- cancer confined to the epidermis
 - non-invasive at this stage
 - can track down hair follicle
 - can become an invasive SCC
 - can be difficult to completely clear



SCC: low risk (Keratoacanthoma)

Incidence

- commonly in fair skinned middle-aged to elderly
- fair skin, exposure to UVR or chemical carcinogens, genetic abnormalities, certain medications

Pathogenesis

- poorly understood
- potential contributing factors that influence epidermal cell proliferation, cell adhesion, cell survival, apoptosis

Presentation

- 1 - 2 cm nodule with central keratin on sun-exposed skin
- 3 phases: proliferative (weeks), maturation (months), regression



SCC: low risk (Invasive)

Presentation

- commonly at the head, neck, hands, mucosa
- dull red, firm, poorly defined plaque or domed nodule with central yellow keratin scale

Prognosis

- usually successfully treated, however persistent/ recurrent tumors can penetrate underlying tissues and spread to lymph nodes, distant organs



SCC: high risk

Incidence

- 9,000 – 12,000 annual deaths in U.S.
- 3-4% overall metastatic rate of SCC
- high risk SCC >20% risk of metastasis

Immune suppressed

- pts with 2-9 SCCs have
 - double the risk of local recurrence
 - triple the likelihood of nodal invasion



Work Group; Invited Reviewers; Kim JYS, Kozlow JH, Mittal B, Moyer J, Olenecki T, Rodgers P. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018 Mar;78(3):560-578.

SCC: high risk

Location: mucosal lip constitute high risk tumor independent of size

- scalp vertex, central face, eyelids, eyebrows, periorbital skin, nose, lips, chin, mandible, pre-postauricular, temple, ear, genitalia, hands, feet, digits, mucosa
- site of scar, chronic inflammation, prior radiation, PUVA

Size: >1 cm head & neck,

>2 cm trunk-exts: 3x metastatic rate of smaller tumors

Depth: of invasion >2 mm

History: older, male, immunocompromised

Histology: inflammation and infiltrative strands, single cells, small nests

- moderately-poorly differentiated, peri-neural, peri-vascular, Single Cell, recurrent
- adenoid/acantholytic, adenosquamous, desmoplastic, metaplastic

SCC: management

- low-risk SCC
 - EDC: small, superficial, in situ lesions in low-risk, in non hair-bearing sites
 - Excision: 4-6 mm surgical margin; cure rates generally > 95%
- high-risk SCC
 - Mohs Micrographic Surgery
 - 100% assessment of surgical margin
 - cure rates generally > 97%
 - XRT: for pts who are not surgical candidates

The risk of local, regional, or distant recurrence is the most important factor to consider

SCC: Mohs Micrographic Surgery

High Risk Lesions

- out-pt surgical procedure performed by Dermatologist with advanced training
- pathology performed during the procedure to assess for tumor-free margins
- to provide the highest cure rate for high-risk tumors
 - 97% Mohs cure rates for primary SCC
- to spare greatest amount of healthy tissue
- to provide adjuvant therapy for (+) margins, recurrent tumors

Mohs “Appropriate Use Criteria”

- 270 different scenarios based on pt or tumor characteristics for which MMS would be appropriate, equivocal or inappropriate

AAD/ ACMS/ ASDSA, ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association and the American Society for Mohs Surgery. *J Am Acad Dermatol* 2012; 67:531-50.

Mohs

Pre-op



Tumor Clearance



Repair



Case #2

64 yr F

PCP prescribed triamcinolone cream
for psoriasis but the lesion isn't healing



Basal Cell Carcinoma (BCC)

- most common human malignancy affecting >3 million pts/yr
- develop from basal cell layer of epidermal keratinocytes
- result from exposure to cumulative or intensive UVR or heavy metals
- lead to DNA mutations which inactivate patched (PTCH) tumor suppressor gene
- most successfully treated with surgical excision
- some lesions may be treated with topical therapy or radiotherapy
- ~40% of pts will develop another BCC within 5 yrs of the 1st

Question 2

Which sub-type of Basal Cell Skin Cancer presents a high risk for recurrence?

- A. Superficial
- B. Nodular
- C. Micronodular
- D. Pigmented

Basal Cell Carcinoma

- grows slowly; common sub-types
 - nodular (nBCC)
 - pigmented (pBCC)
 - superficial (sBCC)
- rare metastatic spread however; certain BCC subtypes are aggressive & locally destructive
 - micronodular (mnBCC)
 - morpheaform/Sclerosing



BCC: low risk

small, primary, well-defined borders, no nerve involvement, immunocompetent pts

Nodular BCC

- smooth, pearly, translucent, pink, lesions with telangiectasias

Pigmented BCC

- speckled, brown, blue, black melanin in lesions; darker skin types
- bleeding & ulceration → rolled border



low risk BCC: management

Electrodesiccation and Cautery

- FDA approved for small BCC's at low-risk sites
- 95% cure rate for primary lesions
- 1st line treatment for primary superficial BCCs
 - <2 cm on the trunk or extremities



low risk BCC: management

Excision

- 3 - 5 mm surgical margins
- treatment of choice for low-risk BCCs
- Mohs for incompletely excised tumors

Cure rates for low-risk tumors

- 95%

Cure rates for larger and high-risk tumors

- 88% $\geq 10\text{mm}$ tumor
- 83% recurrent tumor
- 82% $\geq 20\text{mm}$ tumor



BCC: high risk

High risk characteristics

- >6 mm, scalp, ears, eyes, nose, lips, fingers, toes, genitalia
- perineural invasion, perivascular invasion
- Recurrent, poorly-defined clinical borders
- history of radiation therapy at site, Immunocompromised pt
- Micronodular / Infiltrative
- microscopic islands of tumor cells beyond the clinical margins
- Morpheaform / Sclerosing
- pale, waxy plaques; extends far beyond clinical margins



high risk BCC: management

Mohs Micrographic Surgery

- gold standard of care
- 99% cure rate for primary lesions
- high-risk histology
 - morphea, infiltrative
- high-risk locations
 - scalp, ears, eyes, nose, lips, genitalia, digits
- recurrent lesions

Indications: { recurrent } { size } { tissue sparing } { tumor type } { prev. radiation } { location } { poorly defined }

Other: _____ Mohs Tech: Mark Gerry Amanda

Closure type: V → Y Adv Flap Slide Color: Tan

Closure comments: _____

Mohs Accession #: 13-845 Surgeon: MM Fellow: _____ Resident: Lazareth or Cosenza

Stage I	Stage II	Pre Op Picture
		<input checked="" type="checkbox"/>
		<input checked="" type="checkbox"/>
		<input type="checkbox"/>

Post Op Size: 1.4 x 1.0 cm Closure Size: _____ cm or Flap

Subcutaneous suture: 4-0 Monocryl Cutaneous suture: 6-0 PDS

Ablative modalities like Mohs and excisional surgery have the advantage of examining tissue under the microscope to determine how completely the tumor was removed

Uncommon Non- Melanoma Skin Cancers

Question 3

Which skin cancer has a recurrence rate even more aggressive than melanoma?

- A. Merkel Cell Carcinoma
- B. Cutaneous B-cell Lymphomas
- C. Cutaneous T-cell Lymphoma
- D. Dermatofibrosarcoma Protuberans

Merkel Cell Carcinoma

- aggressive tumor associated with a high rate of recurrence and poor prognosis
- disease-recurrence data are not captured in national databases, but recurrence rates range from 27%-77%
- prospective cohort study included 618 MCC pts enrolled in a Seattle-based data repository 2003-2019 showed 223 experienced disease recurrence
- MCC recurrence rate (38%) was notably > melanoma (19%), SCC (5%-9%), BCC (1%-2%) following definitive treatment
- >90% of MCC recurrences occur within 3 years



McEvoy AM, Lachance K, Hippe DS, Cahill K, Moshiri Y, Lewis CW, Singh N, Park SY, Thuesmunnn Z, Cook MM, Alexander NA, Zawacki L, Thomas H, Paulson KG, Nghiem P. [Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis](#). JAMA Dermatol. 2022 Apr 1;158(4):382-389. doi: 10.1001/jamadermatol.2021.6096. PMID: 35195657; PMCID: PMC8867389.


Cutaneous B-cell Lymphomas

2 main types of lymphocytes can develop into lymphomas:

- B lymphocytes (B cells) & T lymphocytes (T cells)

Cutaneous B-cell Lymphomas (CBCL)

- constitute 85% of all Non-Hodgkin Lymphoma (NHL)
- hyper-reactive inflammatory response
 - due to immunodeficiency disorder, viral or bacterial infection
- slow-growing subtypes
 - Primary Cutaneous Follicle Center Lymphoma
 - Primary Cutaneous Marginal Zone B-Cell Lymphoma
- uncommon subtypes
 - Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type
 - Primary Cutaneous Diffuse Large B-Cell Lymphoma, Other



Cutaneous T-cell Lymphoma

- class of non-Hodgkin's lymphoma, > 50 yr, male, Black
- malignant helper T-cells migrate to the skin
- rare, unclear cause, can metastasize

Sub-types

- Mycosis Fungoides (MF)
- Sezary Syndrome (SS): rare, aggressive

Presentation (may have 1 stage or a combination)

- *Early*: localized or widespread, ill defined, scaly, pink-red plaques
- *Patch*: sharply demarcated, red-pink, scaly atrophic, mottled, telangiectatic
- *Plaque*: dusky red-brown, patches, plaques buttocks, hips, thighs, flexural ext
- *Tumor*: red-brown expanding nodules which may ulcerate



Dermatofibrosarcoma Protuberans

- uncommon locally aggressive cutaneous sarcoma
- can attain massive "protuberant" dimensions
- may ulcerate, bleed, become painful
- becomes fixed to deeper structures in late disease
- M=F, Blacks > Whites, 30-50 yr, 6% in children
- trunk, proximal extremities, scar or tattoo
- MRI: deep extent of the tumor
- CT scan: possible bone involvement or lung metastases



Pigmented Lesions

Question 1

Which nevus may herald the development of vitiligo or melanoma?

- a. Compound Nevus
- b. Nevus Spilus
- c. Halo (Sutton's) nevus
- d. Spitz (Spindle cell) nevus

Congenital Melanocytic Nevi

Congenital Melanocytic Nevi (CMN)

- categorized by the largest diameter
 - Small CMN < 1.5 cm
 - Medium CMN 1.5–20 cm
 - Large CMN 20 – 40 cm
 - Giant CMN 40 – 60+ cm



Congenital Melanocytic Nevus

Risk for malignancy of CMN increases with size

- Small-Medium CMN
 - <1% lifetime melanoma risk -*after puberty*
- Large-Giant CMN
 - 2-5% lifetime melanoma risk
 - 50% of which develop by age 5

Risk for malignancy also increases with

- number of CMN, number of satellite nevi by 1 yr
- location (large lesions at back, buttocks)
- heterogeneity, rugosity, hypertrichosis, nodularity, ulceration



Benign Acquired Nevi

- benign proliferations of "nevus cell" melanocytes
- most remain benign needing only longitudinal observation
- increased risk of melanoma in pts with >50 acquired nevi
- regular Mole Check exams:
- Asymmetry, Border irregularity, Color discrepancy, Diameter >6 mm, Evolution
- Counseling: UVR protection



Benign Nevi: Junctional

- junctional nevus has nests of nevus cells at the junction of the epidermis and the dermis
- brown-black macules with preserved relaxed skin tension lines
- most are seen in children; represent a transient phase in the development of compound nevi
- may be seen on the palms, soles, and genitalia in adults



Benign Nevi: Compound

- compound nevus has nests of nevus cells at the epidermal-dermal junction as well as within the dermis
- central raised papule surrounded by a tan-brown macule
- increase in thickness & pigmentation: late childhood & adolescence
- “combined nevus” has two distinct types of mole within the same lesion; usually blue nevus + compound nevus



Benign Nevi: Blue

- deeply pigmented type of dermal nevus
- congenital or acquired -*adolescence*
- dorsal hands & feet <1 cm solitary, uniformly blue-black, dome-shaped papule
- ddx: traumatic tattoo, nodular melanoma, dermal melanoma metastases
- biopsy if atypical
- “cellular blue nevus” congenital, >1 cm smooth nodule; scalp, face, sacrum, buttocks



Benign Nevi: Spitz

- benign, acquired lesions with abnormal melanocytes which resemble those of melanoma
- arise in children and young adults at the scalp, face, legs with rapid initial growth phase
- <1 cm uniformly pink, tan, red, brown, symmetric, well-circumscribed, dome-shaped, smooth or verrucous papules
- classic Spitz nevi can be monitored; tend to undergo involution over time
- atypical lesions (>1 cm, asymmetrical, very dark, ulcerated) should be excised



Benign Nevus: Halo

- adolescents, young adults
- melanocytic nevus surrounded by halo of depigmentation; back most common
- heralds spontaneous regression of central nevus
- 50% have multiple lesions
- ~20% have vitiligo
- rare: middle-aged-older adults; may represent immune reaction to cutaneous or ocular melanoma
- biopsy if *central nevus* appears atypical



Benign Nevi: Intradermal

- dermal or intradermal nevi have nevus cell nests in the dermis
- develop after adolescence
- skin-colored - tan papules
- “Unna” papillomatous or pedunculated
- “Miescher” dome-shaped papule often found on the face



Question 2

By age 70, a patient with FAMMM syndrome will have a ____% lifetime risk of developing a melanoma.

- a. 1%
- b. 6%
- c. 15%
- d. 100%

Atypical Nevi

- acquired melanocytic neoplasms that share some clinical features of melanoma
- trunk & extremities
- UVR history of tanning, sunburns
- Personal history of ATN/melanoma
- Family history of ATN/melanoma

“ABCDEs”

Asymmetrical, ill-defined Borders,
variegated Color, Diameter >6 mm,
Evolution: changes or symptoms



Atypical Nevi : dermoscopy

Dermatoscope

- handheld, noninvasive, tool used to examine skin lesions
- allows visualization of skin structures not visible to naked eye
- dermoscopic images may be photographed or recorded digitally

transilluminating light source and 10-fold magnifying optics

Non-Polarized dermoscopy

-superficial (epidermal) structures -*blue-white veil*

Polarized dermoscopy

-deeper (dermal) structures -*blood vessels*

several algorithms and scoring systems help clinician to

-differentiate nevus from melanoma

-decide to biopsy or monitor



Atypical Nevi: management

- Biopsy changing, symptomatic or suspicious moles
- pts with ATN have a 3 to 20-fold higher risk of developing melanoma
- **Dysplastic Nevi are** described by pathologists as "nevus with architectural disorder" with specification of the degree of melanocytic atypia present
- **mildly and moderately DN** with clear histologic margins
 - do *not* need re-excision
- **mildly DN** with positive histologic margins but no clinically residual pigmentation
 - do *not* need re-excision
- **moderate-severe and severely DN** with positive margins
 - may benefit from re-excision to confirm the diagnosis and exclude melanoma
- **severely DN** with or without residual pigment in the initial excision specimen
 - may benefit from conservative re-excision with 2-3 mm margins

Familial Atypical Multiple Mole Melanoma (FAMMM) Syndrome

- greatest risk for melanoma in pts with:
 - PMH or FMH of melanoma
 - multiple nevi
 - familial atypical multiple mole and melanoma (FAMMM) syndrome
- FAMMM: pts with >50 melanocytic nevi and FMH of melanoma
- potential precursor for melanoma (*superficial spreading*)
 - 1.3% lifetime risk of melanoma in general population
 - 6% lifetime risk of melanoma (also ocular melanoma) in pts with ATN
 - 15% lifetime risk of melanoma in pts with ATN + FMH of melanoma
 - 100% lifetime risk of melanoma by age 70 in pts with FAMMM

Pt Education for FAMMM pts

- **UVR protection:** shade, clothing, sunglasses, broad-spectrum sunscreen
 - fewer nevi in children who use sunscreen
 - 50% reduction of primary melanoma with regular application of sunscreen
 - increased risk of melanoma with tanning bed use
- **regular skin self-examination**
 - ABCDEs
 - 50% of melanomas are first detected by pts
 - may increase early detection, reduce incidence, reduce advanced disease
- **lifelong melanoma follow-up**
 - routine ophthalmologic and gynecologic examination
 - screening of family members
 - genetic counseling (FAMMM/melanoma)

Case #3

71 yr M

- dark lesion at rt forearm
- delayed access to Derm due to Covid closures
- bubbling with hydrogen peroxide but not healing



Question 3

Which of the following is the most significant risk factor for the lifetime development of cutaneous melanoma?

- a. Skin type I (fair skin)
- b. History of > 6 atypical nevi
- c. History of blistering sunburns
- d. Family history of melanoma

Melanoma: predisposing factors

History

- new, changing lesion
- PMH / FMH of melanoma
- excessive sun exposure and/or tanning bed use
- severe sunburns in youth
- FAMMM, xeroderma pigmentosum
- hx of PUVA, Immunosuppression

Physical

- light-complexioned phototype
- red or blond hair
- light eye color
- presence of a large number of melanocytic nevi
- atypical melanocytic nevi

Melanoma: introduction

- incidence increases with age
- early diagnosis improves outcome & survival rates
 - most are detected by pts themselves however, melanomas detected by clinicians tend to be thinner, more curable tumors
 - thin melanomas confined to the epidermis are associated with prolonged disease-free survival
 - ideally surgically excised before/during horizontal "radial" growth phase
- dermal invasion during "vertical" growth phase has metastatic potential
 - increased tumor thickness "Breslow depth" increases risk of metastases
 - Breslow depth >1 mm is associated with limited survival

Melanoma: clinical

- 70% arise de novo
- 30% arise within an existing nevus
 - present with focal area of color change
- early S&S:
 - flat during horizontal growth phase
 - increase in size, change of color or shape, itching
- late S&S
 - thickened, raised during vertical phase
 - tender, bleeding, crusting, ulceration
- not all melanomas follow the ABCDEs (i.e., amelanotic)



Melanoma: superficial spreading

- most common histologic subtype, ~70%
- >60% diagnosed as thin, highly curable tumors
- subtype most likely to be associated with a pre-existing nevus
- predilection: back, lower extremities (women)
- variably pigmented macule or thin plaque with an irregular border
- size ranges from a few mms to several cms
- multiple shades of red, blue, black, gray, white



Melanoma : nodular

- 2nd most common subtype; 15-30%
- darkly pigmented, symmetrical papules or nodules
- often uniform blue-black color, may have pink hue,
- no identifiable radial growth phase
- appear to enter the vertical growth phase from their inception, resulting in thicker tumors (>2 mm) at diagnosis



Lentigo Maligna & Lentigo Maligna Melanoma

- tan-brown macule in chronically sun-damaged skin
- enlarge over years with darker, asymmetric foci of pigmentation, color variegation, and raised areas

Lentigo Maligna

- in situ melanoma
- changes in LM signify vertical growth

Lentigo Maligna Melanoma

- 10-15% of all melanomas
- rising incidence particularly in older pts



Melanoma: acral lentiginous

- <5 % of all melanomas
- most common subtype in pts with skin of color:
 - 60-72% in African Americans
 - 29-46% in Asian Americans
- 5 yr relative survival
 - 93% Whites : 69% AA
 - reduced access to care, perceived lower risk, atypical sites
 - later diagnosis, timing of detection
- palmar, plantar, subungual
- dark brown-black, irregularly pigmented macules
- dermal invasion: larger lesions, raised areas, ulceration, bleeding



Melanoma : acral subungual

- arises from the nail matrix
- longitudinal, brown/black band in the nail
- with/without nail dystrophy
- may present as a mass below the nail plate with ulceration and nail plate destruction
- can mimic benign conditions: onychomycosis, paronychia, warts, calluses



“Hutchinson sign” longitudinal pigmentation extending to the proximal nail fold or distal digit

Melanoma: amelanotic

- ~2-10% of all melanomas
- *all* subtypes can present as amelanotic or hypomelanotic
- most commonly seen in nodular and desmoplastic melanomas
- pink/red macules, papules, or nodules, often well-defined borders
- benign appearance challenges and delays diagnosis



Melanoma: Spitzoid

- resemble Spitz nevi, both clinically and histologically
- red (amelanotic), brown, black, blue papules or nodules
- often round in shape and uniform in color
- may be crusted and ulcerated
- head or extremities



Melanoma: desmoplastic

- rare but histologically and clinically distinct variant
- slowly growing plaque, nodule
- usually amelanotic in chronically sun-exposed areas of older pts
- may resemble NMSC



Melanoma: histology

Prior to any intervention

- document location, color, size, pattern
- photograph lesion and local landmarks
- carefully palpate local lymph nodes

CLINICAL IMPRESSION/HISTORY
CD13-64266 (1 cm lesion). Suture at 12 o'clock.

FINAL MICROSCOPIC DIAGNOSIS
A. Left upper extremity, Excision:
MALIGNANT MELANOMA IN THE DERMIS, INVASIVE TO A DEPTH OF APPROXIMATELY 2.5 MM; THE MARGINS ARE FREE.

Type: Unclassified
Tumor (Breslow) thickness: 2.5 mm
Anatomic level of invasion (Clark level): IV
Ulceration: Not identified
Dermal mitotic rate: 2 mitoses/ mm2
Microsatellitosis: Not identified
Vertical growth phase: Present
Regression: Not identified
Angiolymphatic invasion: Present
Neurotropism: Focally present
Tumor infiltrating lymphocytes: Non-brisk
Precursor lesion: Not identified

Comment: Multiple tissue levels show a dermal melanocytosis consisting of nests and single cells of melanocytes arranged as irregular aggregates and single cells in the papillary and reticular dermis. There are foci of lymphovascular invasion. Immunostain show that the lesional cells are positive for MART-1. The lack of a junctional component and the presence of lymphovascular invasion are concerning for a metastasis. There is also a separate lentiginous compound nevus that appear completely excised. There is also a wound and a scar, consistent with prior surgical site. Clinicopathologic correlation is recommended. This case was reviewed by Dr. Julie Reimann who concurs with the above interpretation.

Breslow thickness:
strong predictor of metastasis
>1 mm limits survival

Ulceration, invasion of
nerves and vessels

Immunohistochemical staining
S-100, Sox10, MART-1, HMB-45
tyrosinase

Melanoma: diagnostics

Sentinel Lymph Node Biopsy (SLNB)

- determines presence of micrometastasis which helps to stage cancer
- indicated for Breslow ≥ 0.8 mm
- positive lymph nodes: non-tender, firm-hard, increase in size quickly

Gene Expression Profiling (GEP)

- melanoma prognosis identifies the risk of recurrence or metastasis in pts with Stage I, II, and III melanoma
- based on the biologic profile of genes within their tumor tissue
- *CDKN2A* & *BRAF* genes implicated in development of melanoma

- **Objective:** Identify factors associated with differences in melanoma survival in 2 age groups: adolescents and young adults (AYAs; ages 15-39) and older adults (ages 40-64)
- **Methods:** This population-based registry study included all cases (n=81,597) of cutaneous melanoma diagnosed at ages 15-64 from 2004-2015 in CA
- **Results:** AYA pts with Stage IV melanoma, thicker tumors and public insurance had worse survival than was observed among older adults
- **Conclusions:**
 - Survival was much worse for AYAs with stage IV melanoma than observed among older adults
 - Greater awareness, suspicion and screening is critical to improve early melanoma detection and survival in adolescents and young adults

Melanoma Survival by Age Group: Population-Based Disparities for Adolescent and Young Adult Patients by Stage, Tumor Thickness, and Insurance Type. KY Wojcik, M Hawkins, A Anderson-Mellies, et al. Published: JAAD, January 04, 2023. DOI: <https://doi.org/10.1016/j.jaad.2022.10.063>

Melanoma: management

Wide Surgical Excision

- Dermatology Surgeon, Surgical Oncologist, Plastic Surgeon, General Surgeon

Wide Surgical Excision

0.5-1 cm margin: melanoma in situ

1 cm margin: Breslow ≤ 1 mm

1-2 cm margin: Breslow $>1-2$ mm

2 cm margin: Breslow > 2 mm

- worse prognosis: subungual, plantar, palmar, mucosal lesions
- adjuvant XRT: may be indicated if location precludes adequate resection or if particularly high risk of recurrence

Consultation/Collaboration

- Dermatology, Pathology, Surgical – Medical - Radiation Oncology, and/or Tumor Board

Melanoma: oncology

- most cases of melanoma are diagnosed at an early stage when surgical excision can be curative however,
- pts may present with metastatic disease or may develop metastases after initial treatment
- **Chemotherapy:** Stage IIIB-IIIC
 - interleukin-2
 - interferon alfa 2b
- **Immunotherapy:**
 - checkpoint inhibitors
 - [CTLA-4] inhibitors
 - cytotoxic T lymphocyte-associated protein 4
 - LAG-3 inhibitors
 - [BRAF plus MEK] inhibitors targeted therapy

Melanoma: pt education

- Monitoring
 - baseline TBSE then q3 mo yr 1; q 4 mo yr 2; q6 mo yr 3+
 - includes lymph node and liver palpation
 - CT Scan of head, chest, abdomen
 - annual TBSE for 1st degree relatives
- >20% of melanoma pts: develop a new melanoma in situ
 - 5–10% of melanoma pts: develop a 2nd invasive melanoma
 - Self Skin Exam, ophthalmologic examination
 - Annual screening of family members



Benign Neoplasm References

- Bobonich, M & Nolen, M (2015). *Dermatology for Advanced Practice Clinicians*. Philadelphia: Wolters Kluwer.
- Goodheart, H. P. (2009). *Goodheart's Photoguide to Common Skin Disorders (3rd ed.)*. Philadelphia: Lippincott Williams & Wilkins.
- Habif, T.P. (2011). *Skin Disease Diagnosis and Management (3rd ed.)*. China: Elsevier Saunders.

NMSC References

- AAD/ ACMS/ ASDSA, ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association and the American Society for Mohs Surgery. *J Am Acad Dermatol* 2012; 67:531-50.
- Berman B & Villa A. Immune response modulators in the treatment of skin cancer. In: Rigel, DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryr JC & Marks R, eds. *Cancer of the Skin*. Philadelphia, Elsevier Saunders; 2005:503-4.
- Bobonich, M & Nolen, M (2015). *Dermatology for Advanced Practice Clinicians*. Philadelphia: Wolters Kluwer.
- Bricca GM, Brodland D. Mohs surgery: The full spectrum of application. In: Rigel, DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryr JC & Marks R, eds. *Cancer of the Skin*. Philadelphia, Elsevier Saunders; 2005:537-47.
- Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. *J Am Acad Dermatol*. 2019;80:303-317.
- C Bichakjian, A Armstrong, C Baum, J Bordeaux, M Brown, K Busam et al. Guidelines of care for the management of basal cell carcinoma. *J Am Acad Dermatol* 2018;78(3):540-59.
- Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. *J Clin Oncol* 2005; 23:759-65.
- Cooper JS. Radiation therapy in the treatment of skin cancers. In: Rigel, DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryr JC & Marks R, eds. *Cancer of the Skin*. Philadelphia, Elsevier Saunders; 2005:593-604.
- Do DV, Krejci-Papa N, Rogers GS. Surgical excision for skin cancer. In: Rigel, DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryr JC & Marks R, eds. *Cancer of the Skin*. Philadelphia, Elsevier Saunders; 2005:549-60.
- Goldenberg G, Karagiannis T, Palmer JB, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: a retrospective cohort study. *J Am Acad Dermatol*. 2016;75:957.e952-966.e952.
- Hernandez LE, Mohsin N, Yaghi M, Frech FS, Dreyfuss I, Nouri K. [Merkel cell carcinoma](#): An updated review of pathogenesis, diagnosis, and treatment options. *Derm Ther*. December 2021. doi:10.1111/dth.15292
- Kasumagic-Halilovic E, Hasic M, Ovcina-Kurtovic N. A clinical study of basal cell carcinoma. *Med Arch*. 2019;73:394-398.
- Lang P & Maize JC Sr. Basal Cell Carcinoma. In: Rigel, DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryr JC & Marks R, eds. *Cancer of the Skin*. Philadelphia, Elsevier Saunders; 2005:101-104,119.
- Lazareth VL. Dermatologic Care of the Transplant Patient; Part I. *JDNA* 2010; 2(2):59-63.
- Lazareth VL. Dermatologic Care of the Transplant Patient; Part II. *JDNA* 2010; 2(5):198-205.

NMSC References

- Lazareth, VL. Non-Melanoma Skin Cancer in Bobonich, M & Nolen, eds. *Dermatology for Advanced Practice Clinicians: Essential Knowledge and Skills*. Philadelphia: Wolters Kluwer; 2015.
- Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. *J Natl Compr Canc Netw* 2010; 8:836-64.
- Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. *Br J Dermatol* 2006;154:498-504.
- Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs micrographic surgery for primary and recurrent basal cell carcinoma of the face: A prospective, randomized controlled trial with 5 years follow-up. *Lancet Oncol* 2008; 9(12):1149-56.
- Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer 2007. *Nature* 2007; 4:462-9.
- Nguyen TH& Yoon J. Squamous cell carcinoma. In: Rigel, DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC & Marks R, eds. *Cancer of the Skin*. Philadelphia, Elsevier Saunders; 2005:133-141.
- Rees JR, Zens MS, Celaya MO, et al. Survival after squamous cell and basal cell carcinoma of the skin: a retrospective cohort analysis. *Int J Cancer*. 2015;137:878-884.
- Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. *JAMA Dermatol*. 2015;151:1081-1086.
- Spencer JM. Basal Cell Carcinoma. In Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I. *Treatment of skin disease: Comprehensive therapeutic strategies, expert consult 3rd ed*. China, Elsevier Saunders; 2010;616:75-79.
- Tull S, Nunley K, Sengelmann R. Nonsurgical treatment modalities for primary cutaneous malignancies. *Dermatol Surg* 2008; 34:859-872. 28.
- Veness MJ. Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma. *Australas Radiol* 2005; 49:365-76.
- Veness MJ, Harris D. Role of radiotherapy in the management of organ transplant recipients diagnosed with non-melanoma skin cancers. *Aust Radiology* 2007; 51:12-20.
- Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: Presentation, pathogenesis and management. *Cancer Metastasis Rev* 2004;23:389-402.
- Wang JT, Palme CE, Morgan GJ, Gebiski V, Wang AY, Veness MJ. Predictors of outcomes in patients with cutaneous metastatic head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. *Head&Neck*. 2012 Nov;34(11):1524-8.
- Work Group; Invited Reviewers; Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. *J Am Acad Dermatol*. 2018 Mar;78(3):540-559.
- Work Group; Invited Reviewers; Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of cutaneous squamous cell carcinoma. *J Am Acad Dermatol*. 2018 Mar;78(3):560-578.
- Yang JF, You J. Merkel cell polyomavirus and associated Merkel cell carcinoma. *Tumour Virus Res*. 2022 Jun;13:200232. doi: 10.1016/j.tvr.2021.200232.

Nevi, DN & FAMMM References

- Argenziano G, Agozzino M, Bonifazi E, et al. Natural evolution of Spitz nevi. *Dermatology* 2011; 222:256.
- Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. *Pigment Cell Res* 2003; 16:297
- [Cutaneous Tumors and Tumor Syndromes](#) Amy S. Paller MD, Anthony J. Mancini MD, in [Hurwitz Clinical Pediatric Dermatology \(Fifth Edition\)](#), 2016
- Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. *J Med Genet* 2007; 44:99.
- Kim CC, Swetter SM, Curiel-Lewandrowski C, et al. Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. *JAMA Dermatol* 2015; 151:212.
- Krengel S, Scope A, Dusza SW, et al. New recommendations for the categorization of cutaneous features of congenital melanocytic nevi. *J Am Acad Dermatol* 2013; 68:441
- Lai C, Lockhart S, Mallory SB. Typical halo nevi in childhood: is a biopsy necessary? *J Pediatr* 2001; 138:283.
- Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. *J Am Acad Dermatol* 2009; 61:677.e1.
- Mooney MA, Barr RJ, Buxton MG. Halo nevus or halo phenomenon? A study of 142 cases. *J Cutan Pathol* 1995;
- Puig S, Malvehy J. Monitoring patients with multiple nevi. *Dermatol Clin* 2013; 31:565.

Nevi, DN & FAMMM References

- Robinson JK. Surgery of the Skin: Procedural Dermatology - Expert Consult, 2nd ed, Mosby, 2010.
- Soleymani T, Swetter SM, Hollmig ST, Aasi SZ. Adequacy of conservative 2- to 3-mm surgical margins for complete excision of biopsy-proven severely dysplastic nevi: Retrospective case series at a tertiary academic institution. *J Am Acad Dermatol* 2020; 83:254.
- Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. *J Am Acad Dermatol* 2016; 74:395.
- Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. *J Am Acad Dermatol* 2016; 74:395.
- Suh KY, Bolognia JL. Signature nevi. *J Am Acad Dermatol* 2009; 60:508.
- Tannous ZS, Mihm MC Jr, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. *J Am Acad Dermatol* 2005; 52:197.
- Tloughan BE, Orlow SJ, Schaffer JV. Spitz nevi: beliefs, behaviors, and experiences of pediatric dermatologists. *JAMA Dermatol* 2013; 149:283.
- Van Geel N, Speeckaert R, Lambert J, Mollet I, De Keyser S, De Schepper S, Brochez L. Halo naevi with associated vitiligo-like depigmentations: pathogenetic hypothesis. *J Eur Acad Dermatol Venereol*. 2012;26:755–61.
- Wang SQ, Dusza SW, Scope A, et al. Differences in dermoscopic images from nonpolarized dermoscope and polarized dermoscope influence the diagnostic accuracy and confidence level: a pilot study. *Dermatol Surg* 2008; 34:1389.
- Winkelmann RR, Rigel DS. Management of dysplastic nevi: A 14-year follow-up survey assessing practice trends among US dermatologists. *J Am Acad Dermatol* 2015; 73:1056.
- Zeff RA, Freitag A, Grin CM, Grant-Kels JM. The immune response in halo nevi. *J Am Acad Dermatol* 1997; 37:620.

Melanoma References

- Berwick M, Begg CB, Fine JA, et al. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996; 88:17.
- Callahan MK, Kluger H, Postow MA, et al. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol 2018; 36:391.
- Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607.
- Chang CY, Park H, Malone DC, et al. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis. JAMA Netw Open 2020; 3:e201611.
- Do DV, Krejci-Papa N, Rogers GS. Surgical excision for skin cancer. In: Rigel, DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryń JC & Marks R, eds. *Cancer of the Skin*. Philadelphia, Elsevier Saunders; 2005:549-60.
- Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the Skin. In: AJCC Cancer Staging Manual: Eighth Edition, Amin MB (Ed), American Joint Committee on Cancer, Chicago 2017. p.563.
- Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17:1558.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019; 381:1535.
- [Melanoma Survival by Age Group](#): Population-Based Disparities for Adolescent and Young Adult Patients by Stage, Tumor Thickness, and Insurance Type. KY Wojcik, M Hawkins, A Anderson-Mellies, et al. Published: JAAD, January 04, 2023. DOI: <https://doi.org/10.1016/j.jaad.2022.10.063> [Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370:599.](#)
- Myles ZM, Buchanan N, King JB, et al. Anatomic distribution of malignant melanoma on the non-Hispanic black patient, 1998-2007. Arch Dermatol 2012; 148:797.
- Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010; 3:233

Melanoma References

- Regan MM, Werner L, Rao S, et al. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2019; 37:3350.
- Weinstock MA, Risica PM, Martin RA, et al. Melanoma early detection with thorough skin self-examination: the "Check It Out" randomized trial. Am J Prev Med 2007; 32:517. Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607. [Checkpoint inhibition](#)
- Weis E, Shah CP, Lajous M, et al. The association of cutaneous and iris nevi with uveal melanoma: a meta-analysis. Ophthalmology 2009; 116:536.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377:1345.